13 results on '"Lim, Darren Wan-Teck"'
Search Results
2. Bacillus Calmette-Guérin scar flare after an mRNA SARS-CoV-2 vaccine.
- Author
-
Lim, Darren Wan-Teck, Ng, Dorothy Hui Lin, and Low, Jenny Guek-Hong
- Subjects
- *
SARS-CoV-2 , *MEDICAL personnel , *SCARS , *MESSENGER RNA , *VACCINES , *INFLUENZA - Abstract
A 34-year-old woman presented to our outpatient clinic with swelling and erythema over the site of her childhood Bacillus Calmette-Guérin (BCG) vaccination scar, 7 days after receiving her first dose of the BNT162b2 (Pfizer-BioNTech) messenger ribonucleic acid (mRNA) vaccine against SARS-CoV-2 on the ipsilateral arm (Figure 1A). However, BCG scar flares after vaccination with current mRNA vaccines against SARS-CoV-2 appear to be benign, as in the cases presented here, and should not alarm physicians, limit vaccinations, nor be a reason for vaccine hesitancy. Reactivation of the BCG scar has been described with influenza vaccination, childhood Kawasaki disease and viral infections; [2],[3] hence it is possible that non-mRNA-based SARS-CoV-2 vaccines could lead to similar reactions. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
3. Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC).
- Author
-
Fong, Pei Yuan, Tan, Sze Huey, Lim, Darren Wan Teck, Tan, Eng Huat, Ng, Quan Sing, Sommat, Kiattisa, Tan, Daniel Shao Weng, and Ang, Mei Kim
- Subjects
- *
SQUAMOUS cell carcinoma , *PROGRESSION-free survival - Abstract
Aim: Treatment strategies in laryngeal squamous cell cancer (LSCC) straddle the need for long term survival and tumor control as well as preservation of laryngeal function as far as possible. We sought to identify prognostic factors affecting LSCC outcomes in our population. Methods: Clinical characteristics, treatments and survival outcomes of patients with LSCC were analysed. Baseline comorbidity data was collected and age-adjusted Charlson Comorbidity Index (aCCI) was calculated. Outcomes of overall survival (OS), progression-free survival (PFS) and laryngectomy-free survival (LFS) were evaluated. Results: Two hundred and fifteen patients were included, 170 (79%) underwent primary radiation/ chemoradiation and the remainder upfront surgery with adjuvant therapy where indicated. The majority of patients were male, Chinese and current/ex-smokers. Presence of comorbidity was common with median aCCI of 3. Median OS was 5.8 years. On multivariable analyses, high aCCI and advanced nodal status were associated with inferior OS (HR 1.24 per one point increase in aCCI, P<0.001 and HR 3.52; p<0.001 respectively), inferior PFS (HR 1.14; p = 0.007 and HR 3.23; p<0.001 respectively) and poorer LFS (HR 1.19; p = 0.001 and HR 2.95; p<0.001 respectively). Higher tumor (T) stage was associated with inferior OS and LFS (HR 1.61; p = 0.02 and HR 1.91; p = 0.01 respectively). Conclusion: In our Asian population, the presence of comorbidities and high nodal status were associated with inferior OS, PFS and LFS whilst high T stage was associated with inferior LFS and OS. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic.
- Author
-
Lee, Victor Ho-Fun, Adham, Marlinda, Ben Kridis, Wala, Bossi, Paolo, Chen, Ming-Yuan, Chitapanarux, Imjai, Gregoire, Vincent, Hao, Sheng Po, Ho, Cheryl, Ho, Gwo Fuang, Kannarunimit, Danita, Kwong, Dora Lai-Wan, Lam, Ka-On, Lam, Wai Kei Jacky, Le, Quynh-Thu, Lee, Anne Wing-Mui, Lee, Nancy Y, Leung, To-Wai, Licitra, Lisa, and Lim, Darren Wan-Teck
- Subjects
- *
NASOPHARYNX cancer , *COVID-19 pandemic , *DNA viruses , *EPSTEIN-Barr virus , *DELPHI method - Abstract
The effects of the COVID-19 pandemic continue to constrain health-care staff and resources worldwide, despite the availability of effective vaccines. Aerosol-generating procedures such as endoscopy, a common investigation tool for nasopharyngeal carcinoma, are recognised as a likely cause of SARS-CoV-2 spread in hospitals. Plasma Epstein-Barr virus (EBV) DNA is considered the most accurate biomarker for the routine management of nasopharyngeal carcinoma. A consensus statement on whether plasma EBV DNA can minimise the need for or replace aerosol-generating procedures, imaging methods, and face-to-face consultations in managing nasopharyngeal carcinoma is urgently needed amid the current pandemic and potentially for future highly contagious airborne diseases or natural disasters. We completed a modified Delphi consensus process of three rounds with 33 international experts in otorhinolaryngology or head and neck surgery, radiation oncology, medical oncology, and clinical oncology with vast experience in managing nasopharyngeal carcinoma, representing 51 international professional societies and national clinical trial groups. These consensus recommendations aim to enhance consistency in clinical practice, reduce ambiguity in delivering care, and offer advice for clinicians worldwide who work in endemic and non-endemic regions of nasopharyngeal carcinoma, in the context of COVID-19 and other airborne pandemics, and in future unexpected settings of severe resource constraints and insufficiency of personal protective equipment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations.
- Author
-
Chang, Gee-Chen, Lam, David Chi-Leung, Tsai, Chun-Ming, Chen, Yuh-Min, Shih, Jin-Yuan, Aggarwal, Shyam, Wang, Shuhang, Kim, Sang-We, Kim, Young-Chul, Wahid, Ibrahim, Li, Rubi, Lim, Darren Wan-Teck, Sriuranpong, Virote, Chan, Raymond Tsz-Tong, Lorence, Robert M., Carriere, Philippe, Raabe, Christina, Cseh, Agnieszka, and Park, Keunchil
- Subjects
- *
NON-small-cell lung carcinoma , *EPIDERMAL growth factor receptors - Abstract
Background: This study evaluated outcomes among patients with advanced/metastatic non-small-cell lung cancer (NSCLC) treated at Asian centers participating in the global named-patient-use (NPU) program for afatinib. Methods: Patients had progressed after initial benefit with erlotinib or gefitinib, and/or had an EGFR or HER2 mutation, had no other treatment options, and were ineligible for afatinib trials. The recommended starting dose of afatinib was 50 mg/day. Dose modifications were allowed, and afatinib was continued as long as deemed beneficial. Response and survival information was provided voluntarily. Safety reporting was mandatory. Results: 2242 patients (26% aged ≥ 70 years, 96% with adenocarcinoma) received afatinib at centers in 10 Asian countries. Most were heavily pre-treated, including prior treatment with erlotinib or gefitinib. Of 1281 patients tested, 1240 had EGFR mutations (common: 1034/1101; uncommon: 117/1101). There were no new safety signals, the most common adverse events being rash and diarrhea. Objective response rate (ORR) was 24% overall (n = 431 with data available), 27% for patients with common EGFR mutations (n = 230) and 28% for those with uncommon mutations (n = 32); median time to treatment failure (TTF) in these groups was 7.6 months (n = 1550), 6.4 months (n = 692) and 8.4 months (n = 83), respectively. In patients with EGFR exon 20 insertions (n = 23) and HER2 mutations (n = 12), median TTF exceeded 12 months. Conclusions: Patient outcomes in this study were similar to those reported in the analysis of the global NPU. Afatinib achieved clinical benefits in patients with refractory NSCLC. ORR and TTF were similar between patients with tumors harboring uncommon and common EGFR mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Response to fam-Trastuzumab-Deruxtecan in patients with metastatic HER2-positive salivary duct carcinoma: A case series.
- Author
-
Boey, Jaryl Jia Hao, Ng, Kennedy Yao Yi, Krisnadi, Cindy, Lim, Darren Wan-Teck, and Ang, Mei-Kim
- Subjects
- *
CARCINOMA , *METASTASIS - Published
- 2023
- Full Text
- View/download PDF
7. MO2-6-3 Matrisomal abnormality: a predictive biomarker for cancer immunotherapy.
- Author
-
Lim, Su Bin, Lim, Chwee Teck, and Lim, Darren Wan-Teck
- Subjects
- *
HEAD & neck cancer , *IMMUNOTHERAPY , *RECEIVER operating characteristic curves , *NASOPHARYNX cancer , *SQUAMOUS cell carcinoma - Abstract
Background Immune checkpoint inhibitors (ICI) appear particularly promising for head and neck cancers, as evidenced by recent clinical trials. Despite durable antitumor responses in a subset of advanced cancer patients, most head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC) are intrinsically resistant to immunotherapy. Here, we aim to reveal immune infiltrative landscape of HNSCC and NPC and further to identify predictive biomarkers for selection of patients to receive ICI-based treatments. Methods A measure of mRNA deregulation in tumor microenvironment, termed as tumor matrisome index (TMI), was assessed using RNA-seq and microarray-acquired expression datasets. Receiver operating characteristic (ROC) curves and survival data were analyzed to evaluate the diagnostic and prognostic value of TMI, respectively. Parallel analyses of signatures predictive of immunotherapy response, including innate PD-1 resistance signature (IPRES), were performed using Gene set variation analysis (GSVA). Machine learning-based deconvolution algorithm (i.e. CIBERSORT) was applied to all datasets to reveal specific immune cell types associated with TMIhigh tumors. Results TMI achieved a mean AUC value of 0.903 and 0.991 in differentiating normal tissues from NPC and HNSC, respectively. Integrative genomic analyses reveal that TMI is closely associated with IPRES signatures and CIBERSORT-estimated relative abundance of specific immune cell populations. Of clinically targetable immune checkpoints, OX-40L emerged as a promising target for anti-tumor immunity in TMIhigh NPC tumors. Conclusion TMI signatures are integral components of protumoral extracellular matrix. The developed metrics to measure the extent of such matrisomal abnormalities may represent a novel predictive biomarker for cancer immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. MO2-6-3 - Matrisomal abnormality: a predictive biomarker for cancer immunotherapy.
- Author
-
Lim, Su Bin, Te Lim, Chwee ck, and Lim, Darren Wan-Teck
- Subjects
- *
IMMUNOTHERAPY , *BIOMARKERS , *PROGNOSIS , *HEAD & neck cancer , *IMMUNE checkpoint inhibitors - Abstract
Immune checkpoint inhibitors (ICI) appear particularly promising for head and neck cancers, as evidenced by recent clinical trials. Despite durable antitumor responses in a subset of advanced cancer patients, most head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC) are intrinsically resistant to immunotherapy. Here, we aim to reveal immune infiltrative landscape of HNSCC and NPC and further to identify predictive biomarkers for selection of patients to receive ICI-based treatments. A measure of mRNA deregulation in tumor microenvironment, termed as tumor matrisome index (TMI), was assessed using RNA-seq and microarray-acquired expression datasets. Receiver operating characteristic (ROC) curves and survival data were analyzed to evaluate the diagnostic and prognostic value of TMI, respectively. Parallel analyses of signatures predictive of immunotherapy response, including innate PD-1 resistance signature (IPRES), were performed using Gene set variation analysis (GSVA). Machine learning-based deconvolution algorithm (i.e., CIBERSORT) was applied to all datasets to reveal specific immune cell types associated with TMI high tumors. TMI achieved a mean AUC value of 0.903 and 0.991 in differentiating normal tissues from NPC and HNSC, respectively. Integrative genomic analyses reveal that TMI is closely associated with IPRES signatures and CIBERSORT-estimated relative abundance of specific immune cell populations. Of clinically targetable immune checkpoints, OX-40L emerged as a promising target for anti-tumor immunity in TMI high NPC tumors. TMI signatures are integral components of protumoral extracellular matrix. The developed metrics to measure the extent of such matrisomal abnormalities may represent a novel predictive biomarker for cancer immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform.
- Author
-
Yap, Yoon-Sim, Leong, Man Chun, Chua, Yong Wei, Loh, Kiley Wei Jen, Lee, Guek Eng, Lim, Elaine Hsuen, Dent, Rebecca, Ng, Raymond Chee Hui, Lim, John Heng-Chi, Singh, Garima, Tan, Angela, Guan, Guofeng, Wu, Andrew, Lee, Yi Fang, Bhagat, Ali Asgar S., and Lim, Darren Wan-Teck
- Subjects
- *
LABELS , *BREAST cancer , *PROPORTIONAL hazards models , *CUTTING machines , *PROGRESSION-free survival - Abstract
Objectives: We aimed to study the prevalence of CTCs in breast cancer (BC) patients undergoing neoadjuvant or palliative therapy with a label-free microfluidic platform (ClearCell FX), and its prognostic relevance in metastatic BC (mBC). Materials and methods: Peripheral blood samples were collected from 108 BC patients before starting a new line of treatment (“baseline”), majority of whom had mBC (76/108; 70.4%). CTCs were retrieved by dean flow fractionation that enriched for larger cells, and enumerated using immunofluorescence-based staining. Progression-free survival (PFS) in mBC patients was analysed using Kaplan-Meier method; cox proportional hazard models were used for univariable and multivariable analyses. Results: The detection rate of CTCs before starting a new line of treatment was 75.9% (n = 108; median: 8 CTCs/7.5 ml blood) at a cut off of ≥2 CTCs. PFS was inferior for mBC patients with baseline CTC count ≥5 CTCs/7.5 ml blood vs. those with < 5 CTCs/7.5 ml blood (median PFS: 4.3 vs. 7.0 months; p-value: 0.037). The prognostic relevance of CTCs was most significant in patients with HER2- mBC (median PFS: 4.1 vs. 8.3 months; p-value: 0.032), luminal (HR+HER2-) subtype (median PFS: 4.2 vs. 8.3 months; p-value: 0.048), and patients who had one or more prior treatments (median PFS: 4.2 vs. 7.0 months; p-value: 0.02). On multivariable analysis, baseline CTC level (hazard ratio (HR): 1.84, p-value: 0.02) and pre-treatment status (HR: 1.87, p-value: 0.05) were independent predictors of PFS. Conclusions: This work demonstrates the prognostic significance of CTCs in mBC detected using a label-free size-based enrichment platform. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
- Author
-
Tan, Wan-Ling, Ng, Quan Sing, Lim, Cindy, Tan, Eng Huat, Toh, Chee Keong, Ang, Mei-Kim, Kanesvaran, Ravindran, Jain, Amit, Tan, Daniel S. W., and Lim, Darren Wan-Teck
- Subjects
- *
BRAIN metastasis , *EPIDERMAL growth factor receptors , *PROTEIN-tyrosine kinases , *NON-small-cell lung carcinoma , *CENTRAL nervous system cancer , *ANTINEOPLASTIC agents , *BRAIN tumors , *CELL receptors , *DOSE-effect relationship in pharmacology , *LUNG cancer , *LUNG tumors , *GENETIC mutation , *RESEARCH funding , *TREATMENT effectiveness , *RETROSPECTIVE studies - Abstract
Background: Afatinib is an oral irreversible epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) indicated in first-line treatment of advanced EGFR-mutant (EGFRm+) non-small cell lung cancer (NSCLC). Dose dependent side effects can limit drug exposure, which may impact on extracranial and central nervous system (CNS) disease control.Methods: We performed a retrospective study of 125 patients diagnosed with advanced EGFRm+ NSCLC treated with first-line afatinib at a tertiary Asian cancer center, exploring clinicopathological factors that may influence survival outcomes. Median progression free survival (PFS) was estimated using the Kaplan-Meier method. Comparison of PFS between subgroups of patients was done using log-rank tests and Cox proportional hazards models.Results: Out of 125 patients, 62 (49.6%) started on 40 mg once daily (OD) afatinib, 61 (48.8%) on 30 mg OD and 1 (0.8%) on 20 mg OD. After median follow-up of 13.8 months from afatinib initiation, the observed response rate was 70.4% and median PFS 11.9 months (95% CI 10.3-19.3). 42 (33.6%) patients had baseline brain metastases (BM) and PFS of those who started on 40 mg OD (n = 17) vs. 30 mg OD (n = 25) was 13.3 months vs. 5.3 months (HR 0.39, 95% CI 0.15-0.99). BM+ patients who started on 40 mg had similar PFS to patients with no BM (13.3 months vs. 15.0 months; HR 0.79, 95% CI 0.34-1.80).Conclusion: In patients with advanced EGFRm+ NSCLC with BM+, initiating patients on afatinib 40 mg OD was associated with improved PFS compared to 30 mg OD, underscoring the potential importance of dose intensity in control of CNS disease. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
11. Efficacy of Anti-PD1 Blockade in Treating Recurrent or Metastatic Nasopharyngeal Cancer: A Systematic Review and Meta-analysis.
- Author
-
Yeo, Brian Sheng Yep, Song, Harris Jun Jie Muhammad Danial, Soong, Yoke Lim, Chua, Melvin Lee Kiang, Ang, Mei-Kim, Lim, Darren Wan Teck, See, Anna, and Lim, Chwee Ming
- Subjects
- *
NASOPHARYNX cancer , *METASTASIS , *PROGRESSION-free survival - Abstract
Objectives: Anti-PD1 antibody has emerged as a promising immunotherapeutic option in patients with recurrent and/or metastatic nasopharyngeal cancers (RM-NPC). We aim to summarise existing evidence on the use of anti-PD1 antibodies in the treatment of these patients and compare its effectiveness with standard-of-care palliative chemotherapy. Our secondary aim is to explore potential combination therapies with anti-PD1 antibodies.Materials and Methods: PubMed, Embase and Cochrane databases were systematically searched for studies comparing the efficacy of various anti-PD1 antibodies in the treatment of RM-NPC (either as first or second line treatment) from inception to 2 September 2022. Meta-analyses were performed to correlate the various anti-PD1 antibodies with primary endpoints including overall response rate disease control rate (DCR), progression free survival (PFS) and overall survival (OS).Results: Eighteen studies with 1,887 patients met the inclusion criteria. The use of anti-PD1 antibody monotherapy as second-line treatment of RM-NPC revealed an ORR of 23 % (95 % CI = 19 %-28 %) and DCR of 51 % (95 % CI = 42 %-60 %). The ORRs for first-line as well as a combination of first and second-line treatments were 21 % (95 % CI = 15 % - 30 %) and 22 % (95 % CI = 6 % - 56 %, I2 = 75 %) respectively. The 12-month PFS and 12-month OS was also 27 % (95 % CI = 21 %-33 %) and 63 % (95 % CI = 53 %-72 %) respectively. ORR was much higher at 73 % (95 % CI = 32 %-94 %) when anti-PD1 antibodies were combined with Gemcitabine plus Cisplatin.Conclusion: Anti-PD1 antibody demonstrate considerable activity in previously treated RM-NPC patients. Combining anti-PD1 antibodies with gemcitabine and cisplatin chemotherapy enhanced the efficacy of treatment. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
12. Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
- Author
-
Tan, Wan-Ling, Ng, Quan Sing, Lim, Cindy, Tan, Eng Huat, Toh, Chee Keong, Ang, Mei-Kim, Kanesvaran, Ravindran, Jain, Amit, Tan, Daniel S. W., and Lim, Darren Wan-Teck
- Abstract
ᅟ. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy.
- Author
-
Liu, Wai Nam, Fong, Shin Yie, Tan, Wilson Wei Sheng, Tan, Sue Yee, Liu, Min, Cheng, Jia Ying, Lim, Sherlly, Suteja, Lisda, Huang, Edwin Kunxiang, Chan, Jerry Kok Yen, Iyer, Narayanan Gopalakrishna, Yeong, Joe Poh Sheng, Lim, Darren Wan-Teck, and Chen, Qingfeng
- Subjects
- *
ANIMAL experimentation , *APOPTOSIS , *BIOLOGICAL models , *EPSTEIN-Barr virus , *IMMUNOHISTOCHEMISTRY , *IMMUNOTHERAPY , *INTERLEUKINS , *MICE , *MONOCLONAL antibodies , *NASOPHARYNX cancer , *RNA , *STAINS & staining (Microscopy) , *T cells , *XENOGRAFTS - Abstract
Immune checkpoint blockade (ICB) monotherapy shows early promise for the treatment of nasopharyngeal carcinoma (NPC) in patients. Nevertheless, limited representative NPC models hamper preclinical studies to evaluate the efficacy of novel ICB and combination regimens. In the present study, we engrafted NPC biopsies in non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain-null (NSG) mice and established humanized mouse NPC-patient-derived xenograft (NPC-PDX) model successfully. Epstein–Barr virus was detected in the NPC in both NSG and humanized mice as revealed by Epstein–Barr virus-encoded small RNA (EBER) in situ hybridization (ISH) and immunohistochemical (IHC) staining. In the NPC-bearing humanized mice, the percentage of tumor-infiltrating CD8+ cytotoxic T cells was lowered, and the T cells expressed higher levels of various inhibitory receptors, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) than those in blood. The mice were then treated with nivolumab and ipilimumab, and the anti-tumor efficacy of combination immunotherapy was examined. In line with paired clinical data, the NPC-PDX did not respond to the treatment in terms of tumor burden, whilst an immunomodulatory response was elicited in the humanized mice. From our results, human proinflammatory cytokines, such as interferon-gamma (IFN-γ) and interleukin-6 (IL-6) were significantly upregulated in plasma. After treatment, there was a decrease in CD4/CD8 ratio in the NPC-PDX, which also simulated the modulation of intratumoral CD4/CD8 profile from the corresponding donor. In addition, tumor-infiltrating T cells were re-activated and secreted more IFN-γ towards ex vivo stimulation, suggesting that other factors, including soluble mediators and metabolic milieu in tumor microenvironment may counteract the effect of ICB treatment and contribute to the tumor progression in the mice. Taken together, we have established and characterized a novel humanized mouse NPC-PDX model, which plausibly serves as a robust platform to test for the efficacy of immunotherapy and may predict clinical outcomes in NPC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.